Autopsy report · NCT05096234

18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma

“loss of sponsor support”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Stanford University

Sponsor type

University, hospital or other

Conditions

Non-Hodgkin's Lymphoma

Interventions

[ 18F]F-AraG PET

Participants

2

Sites

1

Countries

United States

Trials that died the same way

• Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone
  “Loss of Financial Sponsor” (91% match in meaning)
• Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids
  “Sponsor terminated financial support” (85% match in meaning)
• BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
  “Withdrawal of sponsor support” (84% match in meaning)
• Vasculaire Leg Compression Device for the Treatment of Restless Legs Syndrome - A Prospective Clinical Study
  “sponsor withdrew support” (83% match in meaning)
• Effects of Neuro-Stim System on Pain, Sleep, and Opioid Use
  “Lost funding from sponsor” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.